| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/25/2023 | — | Morgan Stanley | Upgrades | Underweight → Equal-Weight | |
| 05/09/2022 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 12/06/2021 | — | Exane BNP Paribas | Downgrades | Outperform → Neutral | |
| 12/03/2021 | — | Bryan Garnier | Downgrades | Buy → Neutral | |
| 09/20/2021 | — | Deutsche Bank | Downgrades | Hold → Sell | |
| 03/10/2021 | — | Argus Research | Downgrades | Buy → Hold | |
| 02/01/2021 | 3.82% | Cowen & Co. | $110 → $105 | Downgrades | Outperform → Market Perform |
| 01/15/2021 | — | Deutsche Bank | Initiates Coverage On | → Buy | |
| 09/01/2020 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 02/25/2020 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 04/25/2019 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 04/10/2019 | — | Morgan Stanley | Downgrades | Equal-Weight → Underweight | |
| 12/11/2018 | 3.82% | Jefferies | → $105 | Assumes | → Buy |
| 11/26/2018 | -1.13% | Cowen & Co. | → $100 | Upgrades | Market Perform → Outperform |
| 11/19/2018 | — | Goldman Sachs | Upgrades | Neutral → Conviction Buy |
What is the target price for Novartis (NVS)?
The latest price target for Novartis (NYSE: NVS) was reported by Morgan Stanley on September 25, 2023. The analyst firm set a price target for $0.00 expecting NVS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Novartis (NVS)?
The latest analyst rating for Novartis (NYSE: NVS) was provided by Morgan Stanley, and Novartis upgraded their equal-weight rating.
When is the next analyst rating going to be posted or updated for Novartis (NVS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novartis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novartis was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.
Is the Analyst Rating Novartis (NVS) correct?
While ratings are subjective and will change, the latest Novartis (NVS) rating was a upgraded with a price target of $0.00 to $0.00. The current price Novartis (NVS) is trading at is $101.14, which is out of the analyst's predicted range.